Skip to main content
Top
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Epigenetic regulation of RhoB loss of expression in lung cancer

Authors: Julien Mazières, Daniel Tovar, Biao He, Jacobo Nieto-Acosta, Claire Marty-Detraves, Carine Clanet, Anne Pradines, David Jablons, Gilles Favre

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

RhoB is down-regulated in most lung cancer cell lines and tumor tissues when compared with their normal counterparts. The mechanism of this loss of expression is not yet deciphered.

Methods

Since no mutation has been reported in the RhoB sequence, we investigated the epigenetic regulation of RhoB expression by analyzing the effect of HDAC inhibitors and methyltransferase inhibitors, by direct sequencing after bisulfite treatment and by methylation specific PCR.

Results

We first showed that histone deacetylase (HDAC) inhibitors induce a significant RhoB re-expression in lung cancer cell lines whereas only a slight effect was observed with methyl transferase inhibitors. As promoter methylation is the most common epigenetic process in lung cancer, we performed methylation specific PCR and sequence analysis after bisulfite treatment and demonstrated that RhoB was methylated neither in lung cancer cell lines nor in tumor tissues. We also showed that a variable number of tandem repeats sequences in the 5' region of the RhoB gene was involved in HDAC response.

Conclusion

We thus propose that RhoB regulation of expression occurs mainly by histone deacetylation rather than by promoter hypermethylation and that this process can be modulated by specific 5' sequences within the promoter.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mazieres J, Antonia T, Daste G, Muro-Cacho C, Berchery D, Tillement V, Pradines A, Sebti S, Favre G: Loss of RhoB expression in human lung cancer progression. Clin Cancer Res. 2004, 10: 2742-2750. 10.1158/1078-0432.CCR-03-0149.CrossRefPubMed Mazieres J, Antonia T, Daste G, Muro-Cacho C, Berchery D, Tillement V, Pradines A, Sebti S, Favre G: Loss of RhoB expression in human lung cancer progression. Clin Cancer Res. 2004, 10: 2742-2750. 10.1158/1078-0432.CCR-03-0149.CrossRefPubMed
2.
go back to reference Wang S, Yan-Neale Y, Fischer D, Zeremski M, Cai R, Zhu J, Asselbergs F, Hampton G, Cohen D: Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line. Oncogene. 2003, 22: 6204-6213. 10.1038/sj.onc.1206653.CrossRefPubMed Wang S, Yan-Neale Y, Fischer D, Zeremski M, Cai R, Zhu J, Asselbergs F, Hampton G, Cohen D: Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line. Oncogene. 2003, 22: 6204-6213. 10.1038/sj.onc.1206653.CrossRefPubMed
3.
go back to reference Sato N, Fukui T, Taniguchi T, Yokoyama T, Kondo M, Nagasaka T, Goto Y, Gao W, Ueda Y, Yokoi K, Minna JD, Osada H, Kondo Y, Sekido Y: RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line. Int J Cancer. 2007, 120: 543-551. 10.1002/ijc.22328.CrossRefPubMed Sato N, Fukui T, Taniguchi T, Yokoyama T, Kondo M, Nagasaka T, Goto Y, Gao W, Ueda Y, Yokoi K, Minna JD, Osada H, Kondo Y, Sekido Y: RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line. Int J Cancer. 2007, 120: 543-551. 10.1002/ijc.22328.CrossRefPubMed
4.
go back to reference Sahai E, Marshall CJ: Rho-GTPases and cancer. Nature Reviews -Cancer. 2002, 21: 133-142. 10.1038/nrc725.CrossRef Sahai E, Marshall CJ: Rho-GTPases and cancer. Nature Reviews -Cancer. 2002, 21: 133-142. 10.1038/nrc725.CrossRef
5.
go back to reference Ridley AJ: Rho proteins and cancer. Breast Cancer Res Treat. 2004, 84: 13-19. 10.1023/B:BREA.0000018423.47497.c6.CrossRefPubMed Ridley AJ: Rho proteins and cancer. Breast Cancer Res Treat. 2004, 84: 13-19. 10.1023/B:BREA.0000018423.47497.c6.CrossRefPubMed
6.
go back to reference Michaelson D, Silletti J, Murphy G, D'Eustachio P, Rush M, Philips MR: Differential Localization of Rho GTPases in Live Cells. Regulation by hypervariable regions and rhogdi binding. J Cell Biol. 2001, 152: 111-126. 10.1083/jcb.152.1.111.CrossRefPubMedPubMedCentral Michaelson D, Silletti J, Murphy G, D'Eustachio P, Rush M, Philips MR: Differential Localization of Rho GTPases in Live Cells. Regulation by hypervariable regions and rhogdi binding. J Cell Biol. 2001, 152: 111-126. 10.1083/jcb.152.1.111.CrossRefPubMedPubMedCentral
7.
go back to reference Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with rho activity. Mol Cell Biol. 1995, 15: 6613-6622.CrossRefPubMedPubMedCentral Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with rho activity. Mol Cell Biol. 1995, 15: 6613-6622.CrossRefPubMedPubMedCentral
8.
go back to reference Baron R, Fourcade E, Lajoie-Mazenc I, Allal C, Couderc B, Barbaras R, Favre G, Faye JC, Pradines A: RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: Evidenced in vivo by an anti-farnesyl cysteine antibody. Proc Natl Acad Sci USA. 2000, 97: 11626-11631. 10.1073/pnas.97.21.11626.CrossRefPubMedPubMedCentral Baron R, Fourcade E, Lajoie-Mazenc I, Allal C, Couderc B, Barbaras R, Favre G, Faye JC, Pradines A: RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: Evidenced in vivo by an anti-farnesyl cysteine antibody. Proc Natl Acad Sci USA. 2000, 97: 11626-11631. 10.1073/pnas.97.21.11626.CrossRefPubMedPubMedCentral
9.
go back to reference Fritz G, Kaina B, Aktories K: The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem. 1995, 270: 25172-25177. 10.1074/jbc.270.50.29998.CrossRefPubMed Fritz G, Kaina B, Aktories K: The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem. 1995, 270: 25172-25177. 10.1074/jbc.270.50.29998.CrossRefPubMed
10.
go back to reference Canguilhem B, Pradines A, Baudouin C, Boby C, Lajoie-Mazenc I, Charveron M, Favre G: RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling. J Biol Chem. 2005, 280: 43257-43263. 10.1074/jbc.M508650200.CrossRefPubMed Canguilhem B, Pradines A, Baudouin C, Boby C, Lajoie-Mazenc I, Charveron M, Favre G: RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling. J Biol Chem. 2005, 280: 43257-43263. 10.1074/jbc.M508650200.CrossRefPubMed
11.
go back to reference Prendergast GC: Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer. 2001, 1: 162-168. 10.1038/35101096.CrossRefPubMed Prendergast GC: Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer. 2001, 1: 162-168. 10.1038/35101096.CrossRefPubMed
12.
go back to reference Mazieres J, Tillement V, Allal C, Clanet C, Bobin L, Chen Z, Sebti SM, Favre G, Pradines A: Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Exp Cell Res. 2005, 304: 354-364. 10.1016/j.yexcr.2004.10.019.CrossRefPubMed Mazieres J, Tillement V, Allal C, Clanet C, Bobin L, Chen Z, Sebti SM, Favre G, Pradines A: Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Exp Cell Res. 2005, 304: 354-364. 10.1016/j.yexcr.2004.10.019.CrossRefPubMed
13.
go back to reference Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM: Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation, induce apoptosis and suppress human tumor growth in nude mice. J Biol Chem. 2000, 275: 17974-17978. 10.1074/jbc.C000145200.CrossRefPubMed Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM: Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation, induce apoptosis and suppress human tumor growth in nude mice. J Biol Chem. 2000, 275: 17974-17978. 10.1074/jbc.C000145200.CrossRefPubMed
14.
go back to reference Liu AX, Rane N, Liu JP, Prendergast GC: RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol. 2001, 21: 6906-6912. 10.1128/MCB.21.20.6906-6912.2001.CrossRefPubMedPubMedCentral Liu AX, Rane N, Liu JP, Prendergast GC: RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol. 2001, 21: 6906-6912. 10.1128/MCB.21.20.6906-6912.2001.CrossRefPubMedPubMedCentral
15.
go back to reference Adnane J, Muro-Cacho C, Mathews L, Sebti SM, Munoz-Antonia T: Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res. 2002, 8: 2225-2232.PubMed Adnane J, Muro-Cacho C, Mathews L, Sebti SM, Munoz-Antonia T: Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res. 2002, 8: 2225-2232.PubMed
16.
go back to reference Forget MA, Desrosiers RR, Del M, Moumdjian R, Shedid D, Berthelet F, Beliveau R: The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin Exp Metastasis. 2002, 19: 9-15. 10.1023/A:1013884426692.CrossRefPubMed Forget MA, Desrosiers RR, Del M, Moumdjian R, Shedid D, Berthelet F, Beliveau R: The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin Exp Metastasis. 2002, 19: 9-15. 10.1023/A:1013884426692.CrossRefPubMed
17.
go back to reference Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B: Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002, 87: 635-644. 10.1038/sj.bjc.6600510.CrossRefPubMedPubMedCentral Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B: Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002, 87: 635-644. 10.1038/sj.bjc.6600510.CrossRefPubMedPubMedCentral
18.
go back to reference Tovar D, Faye JC, Favre G: Cloning of the human RHOB gene promoter: characterization of a VNTR sequence that affects transcriptional activity. Genomics. 2003, 81: 525-530. 10.1016/S0888-7543(03)00044-2.CrossRefPubMed Tovar D, Faye JC, Favre G: Cloning of the human RHOB gene promoter: characterization of a VNTR sequence that affects transcriptional activity. Genomics. 2003, 81: 525-530. 10.1016/S0888-7543(03)00044-2.CrossRefPubMed
19.
go back to reference He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003, 100: 14133-14138. 10.1073/pnas.2232790100.CrossRefPubMedPubMedCentral He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003, 100: 14133-14138. 10.1073/pnas.2232790100.CrossRefPubMedPubMedCentral
20.
go back to reference Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, Minna JD, Gazdar AF: DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001, 1: 61-67.PubMed Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, Minna JD, Gazdar AF: DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001, 1: 61-67.PubMed
21.
go back to reference Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999, 21: 103-107. 10.1038/5047.CrossRefPubMed Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999, 21: 103-107. 10.1038/5047.CrossRefPubMed
22.
go back to reference Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004, 4: 707-717. 10.1038/nrc1432.CrossRefPubMed Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004, 4: 707-717. 10.1038/nrc1432.CrossRefPubMed
23.
go back to reference Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E: Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene. 1998, 16: 497-504. 10.1038/sj.onc.1201559.CrossRefPubMed Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E: Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene. 1998, 16: 497-504. 10.1038/sj.onc.1201559.CrossRefPubMed
24.
go back to reference Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004, 64: 4717-4720. 10.1158/0008-5472.CAN-04-1389.CrossRefPubMed Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004, 64: 4717-4720. 10.1158/0008-5472.CAN-04-1389.CrossRefPubMed
25.
go back to reference Herman JG: Epigenetics in lung cancer: focus on progression and early lesions. Chest. 2004, 125: 119S-22S. 10.1378/chest.125.5_suppl.119S.CrossRefPubMed Herman JG: Epigenetics in lung cancer: focus on progression and early lesions. Chest. 2004, 125: 119S-22S. 10.1378/chest.125.5_suppl.119S.CrossRefPubMed
26.
go back to reference Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y: Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer. 2004, 46: 171-178. 10.1016/j.lungcan.2004.03.021.CrossRefPubMed Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y: Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer. 2004, 46: 171-178. 10.1016/j.lungcan.2004.03.021.CrossRefPubMed
27.
go back to reference Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BA, Cannon-Albright L, Larsson C, Goldgar DE, Narod SA: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet. 1996, 12: 309-311. 10.1038/ng0396-309.CrossRefPubMed Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BA, Cannon-Albright L, Larsson C, Goldgar DE, Narod SA: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet. 1996, 12: 309-311. 10.1038/ng0396-309.CrossRefPubMed
28.
go back to reference Manenti G, De Gregorio L, Pilotti S, Falvella FS, Incarbone M, Ravagnani F, Pierotti MA, Dragani TA: Association of chromosome 12p genetic polymorphisms with lung adenocarcinoma risk and prognosis. Carcinogenesis. 1997, 18: 1917-1920. 10.1093/carcin/18.10.1917.CrossRefPubMed Manenti G, De Gregorio L, Pilotti S, Falvella FS, Incarbone M, Ravagnani F, Pierotti MA, Dragani TA: Association of chromosome 12p genetic polymorphisms with lung adenocarcinoma risk and prognosis. Carcinogenesis. 1997, 18: 1917-1920. 10.1093/carcin/18.10.1917.CrossRefPubMed
Metadata
Title
Epigenetic regulation of RhoB loss of expression in lung cancer
Authors
Julien Mazières
Daniel Tovar
Biao He
Jacobo Nieto-Acosta
Claire Marty-Detraves
Carine Clanet
Anne Pradines
David Jablons
Gilles Favre
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-220

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine